Evidence map›Paper›PMID 38393642›Full record

ArticlePharmaceutical biology2024

Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents.

Yujin Guo, Beibei Chen, Jinxiu Guo, Pei Jiang, Jianhua Wang, Wenxue Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yujin GuoInstitute of Clinical Pharmacy, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Beibei ChenTranslational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Jinxiu GuoTranslational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Pei JiangInstitute of Clinical Pharmacy, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Jianhua WangTranslational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Wenxue SunTranslational Pharmaceutical Laboratory, Jining First People's Hospital, Shandong First Medical University, Jining, P.R. China.
Shandong First Medical University · CNJining First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextPodophyllotoxin (PPT) derivatives, used in cancer therapy, require development toward enhanced efficacy and reduced toxicity.

objectiveThis study synthesizes PPT derivatives to assess their anticancer activities. MATERIALS AND

methodsCompounds E1-E16 antiproliferative activity was tested against four human cancer cell lines (H446, MCF-7, HeLa, A549) and two normal cell lines (L02, BEAS-2B) using the CCK-8 assay. The effects of compound

resultsAmong the 16 PPT derivatives tested for cytotoxicity, DISCUSSION AND

conclusionsThis research lays the groundwork for advancing cancer treatment through developing and using PPT derivatives. The encouraging results associated with

Indexed as

Antineoplastic AgentsPodophyllotoxinAnimalsApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFemaleHumansMiceMice, NudeMolecular Docking SimulationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTubulinTubulin ModulatorsAntineoplastic AgentsPhosphatidylinositol 3-KinasesPodophyllotoxinProto-Oncogene Proteins c-aktTubulinTubulin Modulatorsapoptosiscompound synthesislung adenocarcinoma epithelialPI3K/akt signalling pathwayTubulin

Identifiers

PMID38393642
PMCPMC10896134
OpenAlexW4392111121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.